All alterations in vital signs should be treated aggressively. Further treatment focuses on supporting cardiovascular function until the toxin is eliminated from the body. No specific antidote has been tested in humans. An animal study using monoclonal antibodies against TTX has been done. Further studies are needed to document the efficacy in humans.
Treatment is symptomatic.
Specific drug efficacy has only been documented anecdotally. Empirically used to minimize systemic absorption of the toxin. May only be of benefit if administered within 1-2 h of ingestion. Network of pores present in activated charcoal absorbs 100-1000 mg of drug per g of charcoal. Does not dissolve in water.